FIG. 1



IX
Major Late L1 L2 L3 L4 L5
VA RNAs
E1AE1B
E3
5 10 15 20 25 30 35
IVa2
E2A
E4
E2B
Orf4
Orf1
Orf6
Orf2
Orf7
6
Orf3
4
3
33000 34000 35000 35938

FIG. 2



10000
1000
100
10
1
mGMCSF (ng/ml)
A549
ADS-12
WI-38
Not infected
TAV-(E1B-19K)mGMCSF
TAV-(L5-E4)mGMCSF

FIG. 3



1000
100
10
1
0.1
GMCSF (ng/ml)
TAV IX-WT L5-Empty
TAV IX-WT L5-IL7
TAV IX-WT L5-GMCSF
TAV IX-GMCSF L5-IL7

FIG. 4




Initial IX-E2 design
IX transcript
IX pA
CMV promoter
BGH pA
E2 pA
E2 transcript
Transgene insertion site
Revised IX-E2 design
IX transcript
IX pA
New pA
CMV promoter
BGH pA
E2 pA
E2 transcript
Transgene insertion site

FIG. 5



TAV Δ19k	TAV hIL12 furin	TAV IXrL5 Empty	WT IXrL5 hIL12	TAV IXrL5 hIL12

FIG. 6



1000
100
10
1
0.1
hIL12 (ng/ml)
191.24
1.30
1.43
TAV-Δ19k
TAV-hIL12-furin
TAV-IXrL5-Empty
TAV-IXrL5-hIL12
WT-IXrL5-hIL12

FIG. 7



35
30
25
20
15
10
5
0
Concentration (ng/ml)
SV40wt
hEF1A
mIL7
mGMCSF

FIG. 8



mIL7 (ng/ml)
Days after infection
+ADP
ΔADP
mGMCSF (ng/ml)
Days after infection
+ADP
ΔADP

FIG. 9

A549 Cells




FIG. 10

HT29 Cells




FIG. 11

ADS12 Cells




FIG. 12

F244 Cells




FIG. 13




FIG. 14

